Haima Therapeutics

Executive Summary

Haima Therapeutics is a preclinical-stage biotechnology company developing SynthoPlate, a synthetic platelet-mimetic nanoparticle designed to treat uncontrolled bleeding and other blood disorders. Founded in 2018 and headquartered in Cambridge, MA, the company aims to address the critical limitations of donor platelet transfusions, such as short shelf life, supply shortages, and the risk of contamination. SynthoPlate leverages Haima's proprietary nanoparticle platform to replicate key platelet functions, including adhesion, aggregation, and clot formation, with the potential for off-the-shelf, portable use in emergency, surgical, and battlefield settings. The company is privately held with limited public disclosures; however, its technology addresses a significant unmet medical need in hemostasis and trauma care, positioning it for potential partnerships or financing to advance toward clinical development.

Upcoming Catalysts (preview)

• Q3 2026Publication of preclinical efficacy data in peer-reviewed journal70% success
• H2 2026Series A financing round to support IND-enabling studies60% success
• TBDFirst-in-human clinical trial initiation (Phase 1)30% success